AwesomeCapital
Search This Blog
Tuesday, May 6, 2025
Sarepta new guidance
Updated Guidance
Prior Guidance
As of May 6, 2025
As of February 26, 2025
Total net product revenues
$2,300 - $2,600M
$2,900 - $3,100M
Combined non-GAAP R&D and SG&A expenses
$1,784 - $2,184M
$1,200 - $1,300M
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-first-quarter-2025-financial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.